View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: February 7, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 6, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Abbott Laboratories: 1 director

A director at Abbott Laboratories bought 10,000 shares at 108.733USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

Boston Scientific Corp: 1 director

A director at Boston Scientific Corp sold after exercising options/sold 160,901 shares at 93.495USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dir...

Hybridan Team
  • Hybridan Team

Hybridan Small Cap Feast: 2 February 2026

2nd February 2026 @HybridanLLP Our daily digest of news from UK Small Caps * A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the Day Admissions: Last Friday 30th Jan, R...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: January 31, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Boston Scientific Corporation: Update to credit analysis following Pen...

Our credit view of this issuer reflects its leading market positions and strong operating performance tempered by an ongoing appetite for acquisitions

Boston Scientific Corporation: Update to credit analysis following Pen...

Our credit view of this issuer reflects its leading market positions and strong operating performance tempered by an ongoing appetite for acquisitions

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: January 26, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Boston Scientific Corporation: Update to credit analysis following Pen...

Our credit view of this issuer reflects its leading market positions and strong operating performance tempered by an ongoing appetite for acquisitions

Medtronic, plc: Key facts and statistics - LTM October 2025

A summary company profile, detailing Medtronic plc’s business operations and financial highlights.

Edwards Lifesciences Corp: 3 directors

Three Directors at Edwards Lifesciences Corp sold/sold after exercising options/gave away 22,120 shares at between 0.000USD and 84.029USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretion...

Abbott Laboratories - September 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Abbott Laboratories: Update following affirmation of Aa3 ratings

Our credit view of this issuer reflects its significant global scale and presence, constrained by its litigation uncertainty with respect to preterm infant formula product lawsuits.

Abbott Laboratories: Key facts and statistics - LTM September 2025

A summary company profile, detailing Abbott Laboratories’ business operations and financial highlights.

Medtronic Plc: 1 director

A director at Medtronic Plc sold 30,000 shares at 101.948USD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson

Hybridan Research: RUA Life Sciences: Journey to a Higher Value

The new accounting date is to September 2025, changed from March, so the next full audited report is for 18 months to be announced in January 2026. The trading-update on 4 November last week included a 12-month contribution from ABISS which was acquired on 9 September 2024. RUA stated its growth strategy is to increase the scale of the medical device and component manufacturing, reduce customer concentration, develop royalties from Biomaterials, and break-even. RUA Life Sciences operates in the...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch